NIH — and some familiar players — back a PhII Alzheimer’s gamble in another stab at the amyloid hypothesis
Cognition Therapeutics has a $76 million grant from the NIH to try out its approach to guarding against the synaptic damage behind the cascade of events that brings on Alzheimer’s. And they’re employing some well-known players in the field for the work.
The New York-based biotech reported Monday morning that the NIH has committed to backing their Phase II trial for CT1812 in 540 early-stage patients over the next 3 years. Cognition says they’ll be carrying out the study along with the NIH-funded Alzheimer’s Clinical Trial Consortium.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.